Skip to main contentSkip to navigationSkip to search

Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference

March 5, 2021


Curasight A/S CEO Ulrich Krasilnikoff will present the company and its future plans, at Økonomisk Ugebrev Life Science Investor Conference 10 March 2021. The presentation will be webcasted live.

For more information please click here

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60



Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.